drugset / Trial / NCT03012971

Summary

A majority of the elderly patients undergo surgery for malignant tumors. For these patients, postoperative tumor recurrence and metastasis are main factors that worsen long-term outcomes. The investigators hypothesize that dexmedetomidine supplemented analgesia in elderly patients after cancer surgery may help to maintain immune function and improve long-term outcomes, possibly by relieving stress and inflammatory response, improving analgesic efficacy and sleep quality, and reducing delirium incidence.

Timeline

Start
2017-01-06
Primary completion
2024-12-11
Completion
2024-12-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 1.25 ug/ml Intravenous
Comparator Morphine Other / unclassified 0.5 mg/ml Intravenous

Indications

No indication recorded.